EGFR and non-small cell lung carcinoma: Notably, a recent study demonstrated that introducing two weakly acidic hydroxyl (-OH) groups to gefitinib significantly enhanced its cytotoxicity against NSCLC cells and mitigated drug resistance 9, implicating lysosomal retention in EGFR-TKI resistance.